Takeda Pharmaceutical announced a revision of its dividend forecast for the fiscal year ending May 2026, increasing the second quarter ending dividend to 70 yen, with an expected annual dividend of 138 yen. This reflects a change in dividend policy aiming to strengthen medium- to long-term shareholder returns.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"8084","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/8084-20260508-02.pdf","jir_short_summary":"Takeda Pharmaceutical announced a revision of its dividend forecast for the fiscal year ending May 2026, increasing the second quarter ending dividend to 70 yen, with an expected annual dividend of 138 yen. This reflects a change in dividend policy aiming to strengthen medium- to long-term shareholder returns.","jir_summary":"### Revision of Dividend Forecast and Policy Change\nTakeda Pharmaceutical revised its dividend forecast released on May 9, 2025, raising the expected year-end dividend for the fiscal year ending March 2026 to 70 yen and projecting an annual dividend of 138 yen. This change is part of a dividend policy shift that emphasizes maintaining financial health while focusing on medium- to long-term corporate value enhancement and shareholder returns. The dividend policy has been revised to target a consolidated payout ratio of 50% or a DOE of 3.5%, aiming for stable profit redistribution.\n\n### Impact on Shareholders and Future Outlook\nThe increase in dividends aims to strengthen shareholder returns and enhance investment appeal. Takeda Pharmaceutical will continue to balance financial health with growth investments and shareholder returns over the medium to long term. Under the new dividend policy starting from March 2027, the company will promote stable dividend payments and aim to improve shareholder value.","jir_financial_highlights":"Year-end Dividend: 70.00 yen (Increase of +2.00 yen from previous forecast)\nAnnual Dividend: 138.00 yen (Increase of +32.00 yen from previous forecast)\nDividend Policy: Prioritizes medium- to long-term and stable shareholder returns (Updated)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #DividendIncrease, #JapaneseStocks","jir_key_figures":"Year-end Dividend: 70.00 yen\nAnnual Dividend: 138.00 yen\nDividend Policy: Medium- to long-term and stable shareholder returns","jir_meta_title":"\u3010Takeda Pharmaceutical\u3011Dividend Increase | May 2026","jir_meta_description":"Takeda Pharmaceutical revised its dividend forecast for fiscal year 2026, announcing a year-end dividend of 70 yen and an annual dividend of 138 yen. It demonstrates a strengthening of medium- to long-term shareholder returns.","jir_og_title":"\u3010Takeda Pharmaceutical\u3011Dividend Increase | May 2026","jir_og_description":"Takeda Pharmaceutical has revised its dividend forecast and announced an increase. The company emphasizes medium- to long-term shareholder return enhancement and stable dividend policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16894,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-45322","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n